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INTRODUCTION 
Systemic lupus erythematosus (SLE) is a chronic, systemic 
autoimmunity with unknown etiology and continuous 
relapse periods depending on several factors including 
environmental and host genetics.1 Patients with SLE have 
an immune response against different intercellular 
antigens leading to immune complexes and sediments in 
vascular parts of different body organs. Immune sediments 
cause local inflammation and tissue damage that leading to 
heightening auto-immune response. Patients with SLE 
cause an immune response against a variety of antigens. 
This response leads to the creation of immune complexes 
that precipitate in various vascular organs of the body. 
Sedimentation of the immune complexes causes local 
inflammation and tissue damage that may aggravate the 
immune response.2 
In recent studies, there was particular attention to levels of 
vitamin D and its role in different diseases. It has been 
observed that vitamin D levels is associated with some of 
chronic diseases such as cardiovascular diseases, 
malignancy and many other autoimmunity diseases such 
as type 1 diabetes mellitus, inflammatory bowel disease 
(IBD), Multiple Sclerosis, undifferentiated connective 
tissue disease, rheumatoid arthritis (RA) and SLE.3 It is 
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also observed that serum vitamin D levels has a reverse 
relationship with SLE activity scores.4-6 
Vitamin D is a steroid hormone that plays an important 
role in calcium metabolism and bone homeostasis, by 
binding to the intracellular vitamin D receptor (VDR) in 
target tissues such as the gastrointestinal tract, kidneys, 
bones, parathyroid glands and skin. It exists in two 
physiological forms, vitamin D2 and vitamin D3. The 
primary source (80%) of vitamin D is the synthesis of 
vitamin D3 in the skin upon exposure to UVB radiation. 
Vitamin D3 is then metabolized in the liver to 25-
hydroxyvitamin D (25(OH) D), which is the intermediate 
usually measured to determine a patient’s vitamin D status. 
25 (OH) D is further metabolized in the kidneys to the 
active form, 1, 25-dihydroxy vitamin D.7 
Recent studies showed that vitamin D had main role in the 
physiologic condition of body and its deficiency related 
with chronic diseases such as calcium disorders, cancers, 
cardiovascular diseases and auto-immune diseases.8-9 
Many studies recently done on the role of vitamin D in the 
modulating the activity of the immune system.10-12 
According to the Shoenfeld et al, study in recent years 
evidence has accumulated regarding the effect of vitamin 
D on the immune system and its different cells. Some 
studies have noted lower vitamin D concentrations in 
patients with SLE but these epidemiological not answer 
the exact response to the hypothesis of vitamin D role in 
SLE.13 
Vitamin D may be considered as a pro-hormone which is 
obtained from 2 distinct sources; to a lesser extent diet, but 
principally by synthesis in the epidermal layer of the skin 
after UV exposure. In the skin, UV rays promote 
photolytic cleavage of 7-dihydrocholesterol into pre-
vitamin D, which is subsequently converted by 
spontaneous thermal isomerization into vitamin D3.14 
Interferon has been vastly evaluated in lupus pathogenesis 
during past recent years. IFN-α is a pleiotropic cytokine 
influencing different kinds of cells in lupus. High levels of 
IFN-α in patient with SLE has been reported comparing 
with healthy people.15-18 IFN-α is able to affect production, 
progression and pathogenesis of SLE as it influences the 
function and activation level of main immunity cells and 
acts as a bridge between innate and acquired immunity.15 
Vitamin D supplementation in SLE patients was 
associated with decrease in inflammatory cytokines and 
markers: IL-1, IL-6, IL-18, TNF-α, erythrocyte 
sedimentation rate (ESR); vitamin D supplementation was 
also associated with a reduction in autoantibodies and 
elevation in complement level.19,20 Vitamin D treatment 
enhanced T-reg cells and production of T helper 2 
cytokines; a correlation was found between disease 
activity and change in 25(OH)D in deficient patients 
following treatment; and vitamin D treatment even showed 
improvement in disease activity and fatigue among 
juvenile-onset SLE.21-23 
IFN-α can be a marker of disease activity and low levels in 
treated patients can express the response to treatment. 
Vitamin D levels have reverse relationship with disease 
activity. So, it is possible that there would be a relationship 
between IFN-α levels and vitamin D levels in patients with 
SLE. There is only one study investigating this 
relationship and expressing that there is an obvious 
negative relationship between vitamin D levels and IFN-α 
level, so that with high level of vitamin D, IFN-α is low 
and disease has lower activity.24 This study aims at 
investigating the relationship between vitamin D and IFN-
α level with disease activity in SLE patients. 
METHODS 
This is a case-control study which was approved in code 
IR.ARUMS.REC.169 by Ardabil University of Medical 
Science ethics committee and carried out on 50 patients 
with lupus and 50 healthy people in Imam Khomeini 
Hospital in Ardabil. All patients provided written informed 
consent and measurement of 25-OH vitamin D level and 
definition of insufficiency were taken from all participants. 
Inclusion criteria 
For this study, authors recruited all patients who fulfilled 
the revised American College of Rheumatology (ACR) 
criteria for the classification of SLE. Control cases 
selected from all patients without any history of auto-
immune diseases. 
Measurement of vitamin D and INT-α 
The serum vitamin D were measured by ELISA kit related 
to the Euroimmun lübeck from Germany country and 
serum interferon alpha levels were measured by the ELISA 
of Bender MedSystems, Inc. Burlingame, California. All 
measurements done by the guideline of each manufactory. 
Measurement of disease activity index 
Authors used the systemic lupus erythematosus disease 
activity index (SLEDAI) questionnaire for diseases 
activity index which had score between 1 and 8 based on 
clinical examination by a clinician and occurrence of some 
disorders. 
Statistical analysis 
Collected data were analysed using descriptive statistical 
methods (frequency, percentage, Mean±SD). Also, 
authors checked the normality of distribution for all data 
by K-S test and then authors used Pearson correlation test 
and scatter plot for obtain the relationship between 
quantitative variables such as 25-Oh vitamin D and 
dsDNA, SLEDAI scores and INF-α. A p<0.05 was 
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considered as significant. All data analysed in SPSS 
version 16.  
RESULTS 
In this paper, 50 patients with SLE and 50 healthy people 
were evaluated that they are matched. Of all patients, 84% 
were female and 16% were male. The mean of 25(OH) 
vitamin D and rate of normal vitamin D in case group 
significantly lower than control group (Table 1). The mean 
of vitamin D and INF-α among male and females in case 
group was 21.82±9.75 and 24.18±12.21ng/ml, respectively 
and the difference between two genders wasn’t significant. 
Table 1: Clinical characteristics of SLE patients and 
healthy controls. 
Variables  SLE  
Healthy 
controls 
p-
value  
Age (year) 33.74±9.12 36.76±8.88 0.09 
Sex (m/f) 5/45 11/39 0.1 
Vitamin D 
(ng/ml) 
23.94±11.93 29.1±11.4 0.02 
INF-α 396.6±54.73 200.38±14.43 0.001 
Vitamin D levels  
Normal 10 (20%) 20 (40%) 
0.06 Insufficient 39 (78%) 30 (60%) 
Deficient 1 (2%) - 
SLEDAI 
Mean 9.46±6.52 -   
Median 8     
Range 0-28     
The mean level of IFN-α in case group with 
396.60±54.73pg/ml significantly higher than control group 
with 200.38±14.42pg/ml (P=0.001). 
IFN-α level of male and females of case group was 
221.60±25.00 and 416.04±60.12pg/ml, respectively that 
shows no meaningful difference. 
Table 2: Correlation between Vitamin D level and 
INF-α and clinical characteristics of SLE patients. 
Variables  
With Vitamin D With INF-α 
r p-value r p-value 
INF-α -0.413 0.003     
SLEDAI -0.492 0.001 0.358 0.01 
Anti-
dsDNA 
-0.417 0.003 0.297 0.03 
There was a meaningful reverse correlation between 
vitamin D level and IFN-α level (Figure 1), SLEDAI 
(Figure 2). There was a meaningful indirect relationship 
between IFN-α level, SLEDAI, anti-dsDNA level with 
Vitamin D. Also, there was a direct meaningful 
relationship between IFN-α level and SLEDAI and anti-
dsDNA level. However, no meaningful relationship was 
observed between vitamin D and IFN-α level in control 
group but the relationship between vitamin D and INF-α in 
SLE patients was indirect and significant. (r=-0.413, 
p=0.003) also the correlation between SLEDAI and INF-α 
in SLE patients was positive and significant (r=0.358, 
p=0.001) (Table 2). 
 
Figure 1: Correlation between vitamin D and INF-α. 
SLE people with normal vitamin D level had meaningfully 
lower IFN-α level, SLEDAI, than people with insufficient 
Vitamin D. Also, we observed that the mean of SLEDAI 
score in SLE people with normal vitamin D level with 
3.2±1.23 significantly lower than healthy people with 
10.4±5.2 (p=0.001). 
 
Figure 2: Correlation between vitamin D                            
and SLEDAI. 
Table 3: Clinical characteristics of SLE patients by 
level of vitamin D. 
p-
value 
Insufficient Normal  
Vitamin D 
levels       
variables  
0.54 34.4±9.6 32.4±6.7 age 
Sex 
0.98 
4 (10.3%) 1 (10%) Male 
35 (89.7%) 9 (90%) Female 
0.03 437.5±64.5 164.4±19.85 INF-α 
0.001 10.4±5.2 3.2±1.23 SLEDAI 
0.002 59.5±6.6 15.9±7.37 Anti-ds DNA 
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Also, authors observed that the mean of INF-α in SLE 
people with normal vitamin D level with 164.4±19.85 
significantly lower than SLE people with Insufficient 
vitamin D level with 437.5±64.5. (p=0.03) (Table 3). 
DISCUSSION 
In this study, it is observed that SLE patients had lower 
vitamin D3 levels than healthy people and also there was a 
significant relationship between high levels of IFN-α with 
SLEDAI and anti-dsDNA. 
It is also observed that 20% of SLE patients had normal 
vitamin D level, 78% had insufficiency and only 2% had 
deficiency. Low levels of vitamin D in SLE patients has 
been reported in Schoindre et al, study that reported 
vitamin D deficiency in 15.9% and insufficiency in 65.9% 
of SLE patients.4 As vitamin D deficient cases were few in 
our group but the total rate of vitamin D deficiency was 
equal in both groups. A recent report showed an 
approximate vitamin D3 deficiency in two third and 
deficiency (less than 10 ng/ml) in about one fifth of SLE 
patients.25 
Low levels of vitamin D3 in SLE patients comparing 
healthy people was reported in different societies.26 In 
present study, it is observed that lupus patients 
significantly had lower vitamin D level than healthy people 
in control group. Normal level vitamin D in SLE patients 
was lower than control group. Similarly, Hamza et al, 
observed than vitamin D levels in SLE patients were 
significantly lower than control group.6 
Vitamin D insufficiency is a common finding among 
Iranians. In a review study, Heshmat et al, expressed that 
vitamin D insufficiency in Iranian males and females have 
been %76.1 and %72.1, respectively.15 Based on different 
studies, vitamin D insufficiency varies in different parts of 
country which can explained through geographical and 
local situation, kind of clothing and nutrition in each 
area.27-32 
Low levels of vitamin D could not be a factor for producing 
and progressing SLE, but its low levels can worsen the 
disease. In present study, a meaningful negative correlation 
was observed between vitamin D level and SLEDAI (r=-
0.492, p=0.001). Low levels of vitamin D are associated 
with higher SLEDAI (r=-0.492, p=0.001) and higher anti-
dsDNA levels (r=-0.417, p=0.003). 
Previous studies expressed that vitamin D3 levels had a 
reverse relationship with SLE disease activity index 
(SLEDAI).5-7 Sumethkul et al, Hamza et al, and Schoindre 
et al, observed that low vitamin D level had a meaningful 
reverse correlation with higher SLEDAI.4,6,33 Also, Mandal 
et al, in a study showed that vitamin D level had a 
meaningfully reverse correlation with SLEDAI and anti-
dsDNA.24 Also, in some studies, no relationship was 
reported between vitamin D level and SLEDAI score.34-37 
The role of IFN-α has recently investigated in pathogenesis 
of SLE. Some studies demonstrated a very strong 
relationship between IFN-α in presence of autoantibodies 
related to SLE such as anti-La, anti-To, anti-Sm, anti-Rnp 
and anti-dsDNA.38,39 Lupus patients with high serum level 
of IFN-α had significantly skin and kidney diseases in most 
of the studies.17,18,39 
Some of the studies showed that IFN-α is related to disease 
activity so, that IFN-α can detect patients with high disease 
activity comparing to other patients.17,18,39,40 It is observed 
that patients with SLE had meaningfully higher IFN-α level 
than healthy people. Also, IFN-α levels had a positive 
correlation with SLEDAI (r=0.35, p=0.01) and anti-
dsDNA (r=0.297, p=0.03).  
Similarly, Dall'era et al, observed that interferon levels 
have meaningful and direct relationship with SLEDAI and 
anti-dsDNA levels and a reverse relationship with C3 
levels.17 Kirou et al, expressed that patients with SLE with 
high IFN-α have higher disease activity index. Also, high 
levels of interferon may lead lower levels of C3 expressing 
increased activity of disease and higher ESR and anti-
dsDNA.17 Mandal et al, observed that patients with SLE 
resistant to treatment had meaningfully higher plasmatic 
IFN-α levels than treating patients and control group. Also, 
Kareem et al, in a study showed that lower levels of vitamin 
D correlated with higher ESR in all patients and with the 
SLEDAI score.41 
However, in some other studies has been expressed that 
IFN-α levels had no relationship with disease activity. Oke 
et al, stated that high levels of interferon do not seem to be 
a specialized biomarker for SLE.42 Moreover, Jolly et al, 
observed no meaningful relationship between IFN-α 
activity with disease activity.43 
It is observed that in different studies, the IFN-α and 
vitamin D levels in patients with SLE are higher than 
healthy people and also related to different disease activity 
and markers. Therefore, it is possible that these two 
markers are connected. In present study, there is 
meaningful negative correlation between vitamin D and 
IFN-α levels. Similarly, Mandal et al, reported a strong 
negative correlation between vitamin D and IFN-α.24 
Ritterhouse et al, observed that patients with vitamin D 
deficiency have higher serum IFN-α activity comparing to 
people without vitamin D deficiency.44 In this study case-
control study we not separated the cases with active disease 
from case with controlled disease, so authors could not 
state certainty the role of low level of vitamin D in these 
two groups. Another limitation of this study was the low 
sample size 
CONCLUSION 
Results showed that vitamin D and INF-a have main role 
in diseases activity in SLE patients and it seem that 
improvement status of vitamin D by reducing the INF-a 
levels could be effective in control the severity of disease. 
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Recommendations  
According to the results of this study, the measure of 
vitamin D in all SLE patients recommended and in all 
patients with a low level of vitamin D, starting treatment 
has been recommended for improve their condition and 
accompanying symptoms. 
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